• |
  • |
  • |
  • |
Donate

Project

PHARM - Aurora Borealis Study

Center:
Fiscal Year:
2022
Contact Information:
Project Description:
A PHASE II MULTICENTER, RANDOMIZED, DOUBLE-BLIND, 12-WEEK TREATMENT, 3-ARM, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF RO7017773 IN PARTICIPANTS AGED 15 TO 45 YEARS WITH AUTISM SPECTRUM DISORDER (ASD) To evaluate the efficacy of 12-week treatment compared with placebo in treating social communication deficits in participants with ASD age 15-45 years old
Keyword(s):
Core Function(s):
Performing Research or Evaluation
Area of Emphasis
Other
Target Audience:
Children/Adolescents with Disabilities/SHCN
Unserved or Under-served Populations:
Specific Groups
Primary Target Audience Geographic Descriptor:
State
Funding Source:
COVID-19 Related Data:
N/A